Home › Malattie autoimmuni › Illinois › Chicago
Studi clinici su Malattie autoimmuni a Chicago, IL
12 studi su Malattie autoimmuni cercano partecipanti presso sedi a Chicago e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
In reclutamentoFase 2
- University of Chicago, Chicago
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
In reclutamentoFase 2/3
- Ann & Robert H. Lurie Children's Hospital of Chicago - Accepting Young Adult and Juvenile Patients, Chicago
- Northwestern Memorial Hospital - Accepting Adult Patients, Chicago
- The University of Chicago Medical Center - Accepting Adult and Juvenile Patients, Chicago
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
In reclutamentoFase 2
- University of Chicago, Department of Medicine: Rheumatology, Chicago
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
In reclutamentoFase 1
- The University of Chicago Medical Center, Chicago
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
In reclutamentoFase 1/2
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
In reclutamentoFase 1/2
- University of Illinois Hospital & Health Sciences System, Chicago
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
In reclutamentoFase 2/3
- Northwestern Memorial Hospital, Chicago
- The University of Chicago Medical Center, Chicago
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
In reclutamentoFase 1/2
- Northwestern Memorial Hospital, Chicago
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
In reclutamentoStudio osservazionale
- Northwestern Memorial Hospital, Chicago
- Rush University Medical Center, Chicago
- University of Illinois at Chicago, Chicago
- e altri 2
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
In reclutamentoFase 1
- Northwestern University, Chicago
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
In reclutamentoFase 1/2
- Northwestern University, Chicago
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- University of Chicago Medical Center, Chicago
Studi su Malattie autoimmuni in altre città
- Houston, TX21 studi
- Washington, DC19 studi
- New York City, NY19 studi
- Philadelphia, PA16 studi
- Durham, NC15 studi
- Boston, MA13 studi
- Los Angeles, CA12 studi
- Dallas, TX9 studi
- Cleveland, OH8 studi
- Milwaukee, WI8 studi
- Atlanta, GA8 studi
- Portland, OR8 studi
Altri studi a Chicago
- Cancro del polmone non a piccole cellule61 studi
- Cancro al seno58 studi
- Cancro (tutti i tipi)51 studi
- Cancro metastatico45 studi
- Cancro alla prostata45 studi
- Obesità41 studi
- Cancro ai polmoni41 studi
- Cancro ovarico36 studi
- Ictus34 studi
- Cancro colorettale33 studi
- Insufficienza cardiaca31 studi
- Sovrappeso28 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.